Ocugen announces FDA has declined to issue Emergency Use Authorization for pediatric use of COVAXIN to prevent COVID-19 in individuals aged two to 18

Sample article from our Health Care Sector

March 7, 2022 (press release) –

Drug maker, Ocugen, Inc. (OCGN), said on Friday that the U.S. Food and Drug Administration or FDA, has declined to issue an Emergency Use Authorization or EUA, for the pediatric use of COVAXIN to prevent Covid-19.

However, the company said it "intends to continue working with FDA to evaluate the regulatory pathway for the pediatric use of COVAXIN."

Earlier, Ocugen had intended to get EUA for the vaccine to prevent Covid-19 caused by SARS-CoV-2 in the children of the age group of 2 to 18 years.


* All content is copyrighted by Industry Intelligence, or the original respective author or source. You may not recirculate, redistrubte or publish the analysis and presentation included in the service without Industry Intelligence's prior written consent. Please review our terms of use.

See our dashboard in action - schedule an demo
Dan Rivard
Dan Rivard
- VP Market Development -

We offer built-to-order health care sector coverage for our clients. Contact us for a free consultation.

About Us

We deliver market news & information relevant to your business.

We monitor all your market drivers.

We aggregate, curate, filter and map your specific needs.

We deliver the right information to the right person at the right time.

Our Contacts

1990 S Bundy Dr. Suite #380,
Los Angeles, CA 90025

+1 (310) 553 0008

About Cookies On This Site

We collect data, including through use of cookies and similar technology ("cookies") that enchance the online experience. By clicking "I agree", you agree to our cookies, agree to bound by our Terms of Use, and acknowledge our Privacy Policy. For more information on our data practices and how to exercise your privacy rights, please see our Privacy Policy.